|
06 Sep 2023 |
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
|
|
06 Sep 2023 |
ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
|
|
06 Sep 2023 |
IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases
|
|
06 Sep 2023 |
Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemother
|
|
06 Sep 2023 |
Update on US regulatory review of Ultomiris in NMOSD
|
|
06 Sep 2023 |
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
|
|
05 Sep 2023 |
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
|
|
05 Sep 2023 |
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
|
|
05 Sep 2023 |
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
|
|
05 Sep 2023 |
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
|
|
05 Sep 2023 |
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
|
|
05 Sep 2023 |
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
|
|
05 Sep 2023 |
XtalPi and Parthenon Enter Into AI-Powered Antibody Discovery Partnership
|
|
05 Sep 2023 |
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
|
|
05 Sep 2023 |
Italfarmaco Group Receives EMA Validation of Marketing Authorization Application for Givinostat in Duchenne Muscular Dystrophy
|
|
05 Sep 2023 |
Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
|
|
05 Sep 2023 |
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
|
|
05 Sep 2023 |
ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
|
|
05 Sep 2023 |
Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia
|
|
05 Sep 2023 |
Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate
|
